PlantForm Corporation, a Canadian biotech firm, has announced that it will begin construction this summer on a new biopharmaceutical lab in Rio de Janeiro with its partner, Brazil-based Axis Biotec Brasil. According to PlantForm’s press release, the joint venture, known as PlantPraxis, “will first develop a biosimilar version of adalimumab (Humira®) for rheumatoid arthritis and other inflammatory disorders.”
PlantForm’s website explains that its proprietary vivoExpress® technology uses genetically-modified tobacco plants to manufacture biologic pharmaceuticals.
